Alpha-fetoprotein

This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (August 2008)

edit

Alpha-fetoprotein
Identifiers
Symbols	AFP; FETA; HPAFP
External IDs	OMIM: 104150 MGI: 87951 HomoloGene: 36278
Gene ontology Molecular function: • transmembrane transporter activity • copper ion binding • nickel ion binding • metal ion binding Cellular component: • extracellular region • extracellular space Biological process: • ovulation (sensu Mammalia) • transport • immune response • sexual reproduction • progesterone metabolic process
RNA expression pattern
More reference expression data
Orthologs
	Human	Mouse
Entrez	174	11576
Ensembl	ENSG00000081051	ENSMUSG00000054932
Uniprot	P02771	Q3TGA3
Refseq	NM_001134 (mRNA) NP_001125 (protein)	NM_007423 (mRNA) NP_031449 (protein)
Location	Chr 4: 74.52 - 74.54 Mb	Chr 5: 91.57 - 91.58 Mb
Pubmed search	[1]	[2]

Alpha-fetoprotein (AFP) is a protein^[1][2] which in humans is encoded by the AFP gene.^[3][4]

This gene encodes alpha-fetoprotein, a major plasma protein produced by the yolk sac and the liver during fetal life. The protein is thought to be the fetal counterpart of serum albumin, and the alpha-fetoprotein and albumin genes are present in tandem on chromosome 4. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin.^[4]

In humans, AFP levels decrease gradually after birth, reaching adult levels by 8 to 12 months. Normal adult AFP levels are low, but detectable; however, AFP has no known function in healthy adults. In normal fetuses, AFP binds the hormone estradiol. AFP is measured in pregnant women, using maternal blood or amniotic fluid, as a screening test for a subset developmental abnormalities, principally increased in open neural tube defects and omphalocoele & decreased in Down syndrome. It is also measured in pregnant women, other adults, and children, serving as a biomarker to detect a subset of tumors, principally hepatocellular carcinoma and endodermal sinus tumors.

Contents 1 Structure and levels 2 History 3 AFP in normal infants 4 AFP tests 4.1 Tests performed on serum 4.1.1 Maternal serum 4.1.2 Tumor marker 4.2 Tests performed on cerebrospinal fluid (CSF) 5 Interpretation of AFP test results 5.1 Maternal serum 5.2 Amniotic fluid 6 Sources of AFP: Normal 7 Sources of AFP: Abnormal 7.1 Tumors 7.2 Other 8 References 9 Further reading 10 See also 11 External links

Structure and levels

AFP is a glycoprotein of 590 amino acids and a carbohydrate moiety. Many functions have been proposed for AFP; an anti-cancer active site peptide has been identified and is referred to as AFPep. AFP is normally produced by the fetal yolk sac, the fetal gastrointestinal tract, and eventually by the fetal liver. Levels of AFP in fetal serum rise until the end of the first trimester of gestation and then fall. Because the fetus excretes AFP into its urine, amniotic fluid levels of AFP tend to mirror fetal serum levels. In contrast, maternal serum levels of fetal AFP are much lower but continue to rise until about week 32.

History

LabCorp, a large US clinical laboratory testing company, began offering AFP screening tests in the early 1980s.^[5]

AFP in normal infants

The normal range of AFP for adults and children is variously reported as under 50, under 10, and under 5 ng/mL.^[6][7] At birth, normal infants have AFP levels 4 or more orders of magnitude above this normal range, decreasing to within it over the first 1–2 years of life.^{[8][9][10][11][12][13]} During this time, the normal range of AFP levels spans approximately 2 orders of magnitude.^[10] Correct evaluation of abnormal AFP levels in infants must take into account these normal patterns.

Very high AFP levels may be subject to hooking (see Tumor marker), resulting in a reported high level that is nonetheless significantly lower than the actual level.^[14] This is important for analysis of a series of AFP tumor marker tests, eg in the context of post-treatment early surveillance of cancer survivors, where the rate of decrease of AFP has diagnostic value.

Elevated alphafetoprotein Classification and external resources
ICD-10	R77.2, Z36.1
ICD-9	V28.1

AFP tests

There are two categories of AFP tests: tests performed on serum (blood plasma), and tests performed on amniotic fluid. Tests performed on serum are further categorized by the reason for performing the test: maternal serum, adult tumor marker, and pediatric tumor marker.

Tests performed on serum

The standard is a quantitative test, reporting a measured concentration of AFP in the sample, but there is also a less expensive qualitative test, reporting only that the concentration is normal or high. The qualitative test is appropriate only in some circumstances.

The resulting test report should specify the assay method and equipment used, and the report of a quantitative test should also provide a reference range for the test result. Many laboratories report reference ranges that are based on all other samples tested in that laboratory, necessarily including samples with abnormal AFP concentrations due to disease. Superior reference ranges are produced by research on healthy subjects.

Maternal serum

Maternal serum AFP (MSAFP) varies by orders of magnitude during the course of a normal pregnancy. MSAFP increases rapidly until about 32 weeks gestation, then decreases gradually. After the pregnancy ends it decreases rapidly, with a half-life of about 5 days.

Typically, MSAFP is measured in the beginning of the second trimester (14-16 weeks). It may be measured alone or as part of a package of routine prenatal screening tests, such as a triple test or quad test.

Because MSAFP test results must be interpreted according to the gestational age, they often are reported in terms of multiple of the median (MoM). Because the median is calculated from tests of other women's pregnancies at the same gestational age, in effect MoM is independent of gestational age. A typical normal range is 0.5 to 2.0 or 2.5 MoM.

MSAFP above normal is seen in multiple gestation, when there is placental abruption, as well as in a number of fetal abnormalities, such as neural tube defects including spina bifida and anencephaly, and abdominal wall defects. Other possibilities are errors in the date of the gestation or fetal demise. Rarely, high MSAFP is due to endodermal sinus tumor (EST) or another germ cell tumor containing EST. These tumors can occur in the pregnant woman (often as an ovarian tumor) or in the fetus.

MSAFP below normal is associated with a smaller number of conditions, including Down syndrome and Trisomy 18. Diabetic patients also have lower levels.

Patients with abnormal MSAFP need to undergo detailed obstetric ultrasonography. The information is then used to decide whether to proceed with amniocentesis. Genetic counseling usually is offered when the screening test result is positive.

Tumor marker

Like any elevated tumor marker, elevated AFP by itself is not diagnostic, only suggestive. Tumor markers are used primarily to monitor the result of a treatment (e.g. chemotherapy). If levels of AFP go down after treatment, the tumor is not growing. In the case of babies, after treatment AFP should go down faster than it would normally. A temporary increase in AFP immediately following chemotherapy may indicate not that the tumor is growing but rather that it is shrinking (and releasing AFP as the tumor cells die). AFP-L3, an isoform of AFP which binds Lens culinaris agglutinin, can be particularly useful in early identification of aggressive tumors associated with hepatocellular carcinoma (HCC).

AFP is the main tumor marker (sometimes with HCG) used to monitor testicular cancer, ovarian cancer, and malignant teratoma in any location: values of AFP over time can have significant effect on the treatment plan.

AFP is normally elevated in infants, and because teratoma is the single most common kind of tumor in infants, several studies have provided reference ranges for AFP in normal infants.^[15][8][12] Perhaps the most useful is this equation: log Y = 7.397 - 2.622.log (X + 10), where X = age in days and Y = AFP level in nanograms per milliliter.^[10]

Tests performed on cerebrospinal fluid (CSF)

In normal infants, AFP in CSF is:^[16]

• median 61 kIU/L (5th-95th centile: 2-889 kIU/L) in infants -69 to 31 days old
• median 1.2 kIU/L (5th-95th centile: 0.1-12.5 kIU/L) in infants 32 to 110 days old

Levels of AFP in CSF decline with gestational age in proportion to levels of AFP in serum^[17]

Interpretation of AFP test results

AFP test results often are reported as either ng/ml or MoM (multiple of the median, where the median is calculated for an appropriate reference population).

Maternal serum

Abnormally elevated AFP in the serum of a pregnant woman can have one or more of these sources:

• a problem with the fetus
• a problem with the placenta
• a tumor or liver disease in the woman
• a normally elevated AFP in the fetus or woman (some people naturally have very high AFP)

Usual follow-up steps include (1) a prenatal ultrasound exam to look for fetal abnormalities and/or (2) measurement of AFP in amniotic fluid obtained via amniocentesis.

Amniotic fluid

AFP in amniotic fluid has one or two sources. The fetus normally excretes AFP into its urine, hence into the amniotic fluid. A fetus with one of three broad categories of defects also releases AFP by other means. These categories are open neural tube defect, open abdominal wall defect, and skin disease or other failure of the interior or exterior body surface.

Abnormally elevated AFP in amniotic fluid can have one or more of many different causes:

• normal elevation. 75% of AF AFP test results in the range 2.0 to 4.9 MoM are false positives: the baby is normal.
• open neural tube defect
• open abdominal wall defect
• congenital nephrosis
• others

Sources of AFP: Normal

Serum alpha-fetoprotein is a fetal serum protein produced by the yolk sac and liver.

Sources of AFP: Abnormal

Tumors

Principal tumors that secrete AFP are endodermal sinus tumor (yolk sac carcinoma), neuroblastoma, hepatoblastoma, and hepatocellular carcinoma.

With regard to hepatocellular carcinoma, AFP is not useful for screening^[18] but is somewhat useful for surveillance after treatment.^[19]

Rare AFP-secreting tumor types include carcinoma in a mixed Müllerian tumor.^[20]

In Wilms tumor AFP is rarely elevated, but when it is elevated it may serve as a marker of disease progression or recurrence.^[21]

There are case reports of elevated AFP associated with teratoma. However, some of these case reports involve infants but do not correct for the normal elevation of AFP in infants, while others ignore the likelihood that teratoma (and other germ cell tumors) may in fact be mixed tumors containing elements of endodermal sinus tumor.

In patients with AFP-secreting tumors, serum levels of AFP often correlate with tumor size. Resection is usually associated with a fall in serum levels. Serum levels are useful in assessing response to treatment.

Other

Increased serum levels in adults are also seen in acute hepatitis, colitis and ataxia telangiectasia.

References

Further reading

See also

• Tumor marker
• AFP-L3

External links

• MeSH alpha-Fetoproteins

v • d • e Tumor markers Reproductive ovarian cancer: CA-125 · CD30 testicular cancer: βHCG · Alpha-fetoprotein/AFP-L3 · CD30 prostate cancer: Prostate specific antigen · Prostatic acid phosphatase · Glutamate carboxypeptidase II · erbB-3 receptor · Early prostate cancer antigen-2 · SPINK1 · GOLPH2 · PCA3 germ cell tumor: NANOG Digestive colorectal cancer: CA 19-9 · Carcinoembryonic antigen pancreatic cancer: CA 19-9 · Carcinoembryonic antigen hepatocellular carcinoma: Alpha-fetoprotein/AFP-L3 Endocrine medullary thyroid cancer: Calcitonin pheochromocytoma: Normetanephrine · Enolase 2 Other breast cancer: CA 15-3 · erbB-2 receptor · erbB-3 receptor lung cancer: Carcinoembryonic antigen · Enolase 2 · Autocrine motility factor neuroendocrine tumors: Synaptophysin brain tumor: PCNA lymphoma: Neprilysin bladder cancer: erbB-3 receptor Note: all are peptide except normetanephrine and PCA3.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

---

No comments have been added.

Your name:
City:
Country:	USA UK India Pakistan UAE Saudi Arabia Germany Afghanistan Albania Algeria Andorra Angola Antigua Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burma Burund Cambodia Cameroon Canada Central African Rep Chad Chile China Columbia Comoros Congo Costa Rica Croatia Cuba Cyprus Czech Republic DR Congo Denmark Djiboutil Dominica Dominican Rep Ecuador Egypt El Salvador Eq Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Grenadines Guatemala Guinea Bissau Guinea Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Laos Latvia Lebanon Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Macau Madagascar Malawi Malaysia Maldives Mali Malta Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Morocco Mozambique Namibia Nauru Nepal Neth Antilles Netherlands New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Rawanda Romania Russia Sao Tome Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Korea South Africa Spain Sri Lanka St Kitts_Nevis St Lucia Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvala UAE Uganda Ukraine Uruguay Uzbekistan Vanuatu Venezuela Vietnam Western Samoa Yemen Yugoslavia Zaire Zambia Zimbabwe
Your comments:
Security check * (Please enter the number into adjoining box)